Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Healthcare Facilities & Services

Delayed Nasdaq Stockholm Other stock markets 03:39:36 2024-04-30 am EDT			5-day change	1st Jan Change
0.0398 ^SEK	+2.58%		-2.45%	-58.11%

Apr. 18	Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	CI
Apr. 17	Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	CI

Prostatype Genomics AB Announces Sales Results for the Third Quarter of 2023

December 21, 2023 at 12:33 pm EST

Prostatype Genomics AB (publ) announced sales results for the third quarter of 2023. The company announced that its net sales for the third quarter of 2023 amounted to approx. SEK 530,000, compared to SEK 109,000 for the same period last year.

Latest news about Prostatype Genomics AB

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	Apr. 18	CI
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	Apr. 17	CI
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results	Apr. 16	MT
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain	Apr. 16	CI
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain	Apr. 16	CI
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States	Apr. 02	CI
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Prostatype Genomics AB Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®	Dec. 22	CI
Prostatype Genomics AB Announces Sales Results for the Third Quarter of 2023	Dec. 21	CI
Prostatype Genomics to Raise SEK48 Million via Rights Issue; Shares Slump	Nov. 07	MT
Prostatype Genomics AB Announces Henrik Nilsson to Leave the Board of Directors Prematurely	Nov. 07	CI
Prostatype Genomics Secures Prostate Cancer Test Order From Swiss Institution; Shares Surge	Nov. 01	MT
Prostatype Genomics AB Receives the First Order of Prostatype in Switzerland from One of the Country's Major University Hospitals	Nov. 01	CI
Prostatype Genomics Appoints New CFO	23-10-31	MT
Prostatype Genomics Appoints Anders Koch as New CFO	23-10-31	CI
Prostatype Genomics AB Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics	23-10-30	CI
Prostatype Genomics’ Prostate Cancer Test Shows Efficiency in Initial Results of Multicenter Study	23-10-25	MT
Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)	23-10-25	CI
Prostatype Genomics CFO to Depart in December	23-09-05	MT
Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company	23-09-04	CI
Prostatype Genomics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Prostatype Genomics AB Provides Revenue Guidance for the Third Quarter of 2023	23-08-17	CI
Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer	23-06-20	CI
Prostatype Genomics AB Announces Executive Changes	23-06-01	CI
Prostatype Genomics AB Announces Board Changes	23-06-01	CI

Chart Prostatype Genomics AB

Duration

Period

More charts

Company Profile

Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.

Sector

Healthcare Facilities & Services

Calendar

2024-05-22 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
PROSTATYPE GENOMICS AB	-58.11%	3.52M
SONIC HEALTHCARE LIMITED	-16.55%	8.43B
RADNET, INC.	+40.93%	3.62B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-35.59%	2.61B
SYNLAB AG	-8.06%	2.48B
DR. LAL PATHLABS LIMITED	-8.00%	2.34B
NEOGENOMICS, INC.	-5.93%	1.94B
FLEURY S.A.	-18.96%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.35%	1.26B
METROPOLIS HEALTHCARE LIMITED	+6.91%	1.1B

Medical & Diagnostic Laboratories